Journal
EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 17, Issue 1, Pages 47-57Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2016.1204234
Keywords
Alzheimer's disease; synaptic dysfunction; amyloid beta; tau protein; neurogranin; biomarker; cerebrospinal fluid; pathophysiology; early diagnosis; precision medicine
Categories
Funding
- AXA Research Fund
- Fondation Universite Pierre et Marie Curie
- 'Fondation pour la Recherche sur Alzheimer', Paris, France
- 'Investissements d'avenir' [ANR-10-IAIHU-06]
- Association for Alzheimer Research (Paris)
- Pierre and Marie Curie University (Paris)
- Pfizer Avid
Ask authors/readers for more resources
Introduction: Synaptic dysfunction and degeneration are early fundamental pathophysiological characteristics of Alzheimer's disease (AD). In addition, synaptic depletion closely correlates with clinical disease severity. Biomarkers that may track synaptic dysfunction in AD are eagerly awaited. Areas covered: Here, we reviewed the significance of the post-synaptic protein neurogranin - particularly enriched in dendritic spines - as a biomarker of early synaptic dysfunction in AD. We also examined its role as a marker to predict disease progression. Expert commentary: Current evidence indicates that neurogranin may serve as a mechanism-of-action biomarker aiding the in vivo investigation of AD-related pathophysiological pathways. Its use may support the development of targeted therapeutic interventions tailored to the individual patient, i.e. 'molecularly' targeted therapies, according to the evolving precision medicine paradigm.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available